Top Health Tools
Top Health Tools

Top Reports
Top Reports
 
Top Articles
Top Articles

Top Reviews
Top Reviews
   
 
WHO Approves Deadly H1N1 Arepanrix Vaccine For Use In Other Countries

Drug giant GlaxoSmithKline says its Arepanrix H1N1 vaccine has been certified by the World Health Organization (WHO), making it available for donors to buy for developing countries.

In a statement issued Tuesday, GlaxoSmithKline PLC said WHO had approved its Canadian Arepanrix vaccine after examining its quality and safety data. The vaccine contains the AS03 adjuvant system, a group of chemical compounds including the neurotoxin squalene.

Last month, Glaxo advised health authorities not to use one batch of its Canadian-manufactured swine flu vaccine because it triggered life-threatening side effects like anaphylactic shock.

Canada recently recalled 172,000 doses of the Arepanrix vaccine after 200 deaths and 36 severe allergic reactions.

Several vaccine makers have promised WHO 156 million doses of swine flu vaccine, which it hopes to start shipping to 95 poor countries this month.

* A full list of h1n1 vaccine ingredients, alerts and warnings.


Reference Sources 102
December 1, 2009
Share/Bookmark
...............................................................................................................

This site is owned and operated by PreventDisease.com 1999-2014. All Rights Reserved. All content on this site may be copied, without permission, whether reproduced digitally or in print, provided copyright, reference and source information are intact and use is strictly for not-for-profit purposes. Please review our copyright policy for full details.
aaa
Interact
volunteerDonateWrite For Us
Stay Connected With Our Newsletter